Related Experiment Videos
Potential novel therapies for chronic obstructive pulmonary disease
1National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK.
Novartis Foundation Symposium
|February 24, 2001
Summary
New treatments for chronic obstructive pulmonary disease (COPD) are needed due to its distinct inflammatory pathways compared to asthma. Research focuses on targeting neutrophilic inflammation, cytokines like tumor necrosis factor-alpha, and oxidative stress for effective COPD therapies.
Area of Science:
- Pulmonary Medicine
- Inflammation Research
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) treatment lags behind asthma despite significant drug development.
- Understanding the cell and molecular basis of COPD is crucial for developing new therapeutic strategies.
- The inflammatory profile in COPD, characterized by neutrophilic infiltration, differs significantly from asthma's eosinophilic inflammation.
Purpose of the Study:
- To review current understanding of COPD pathogenesis and identify novel therapeutic targets.
- To highlight the distinct inflammatory mechanisms in COPD compared to asthma.
- To explore potential anti-inflammatory treatments beyond corticosteroids for COPD.
Main Methods:
- Review of scientific literature on COPD inflammation and potential drug targets.
- Analysis of cellular and molecular mediators involved in COPD pathogenesis.
- Evaluation of emerging therapeutic strategies targeting specific inflammatory pathways.
Main Results:
- Neutrophilic inflammation in COPD is driven by factors like interleukin-8 (IL-8) and leukotriene B4, suggesting receptor antagonists or synthesis inhibitors as potential treatments.
- Tumor necrosis factor-alpha (TNF-alpha) acts as an amplifying cytokine, with strategies like antibodies or TACE inhibitors being explored for its blockade.
- Oxidative stress and peroxynitrite are implicated in COPD, necessitating the development of advanced antioxidants. Steroid-resistant inflammation points to alternative treatments like phosphodiesterase 4 (PDE4) inhibitors, NF-kappa B inhibitors, and p38 MAP kinase inhibitors.
Conclusions:
- COPD requires novel anti-inflammatory approaches due to its steroid-resistant, neutrophilic inflammation.
- Targeting specific inflammatory mediators (e.g., IL-8, TNF-alpha) and pathways (e.g., oxidative stress, PDE4) offers promising avenues for COPD treatment.
- Development of protease inhibitors and other targeted therapies is ongoing to address the complex pathology of COPD.